linjc16/ctgov huggingface dataset:
Effects of Scapular Exercise on Patients With Scapulocostal Syndrome

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the effect of scapular exercise on pain related parameters including pain intensity, 24 hours pain intensity, pressure pain threshold, anxiety and muscle tension in patients with scapulocostal syndrome.

Official Title
-----------------
Effects of Scapular Exercise on Patients With Scapulocostal Syndrome

Conditions
-----------------
Scapular Pain

Intervention / Treatment
-----------------
* Other: scapular exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female Age between 18 - 50 years old The participants have experienced spontaneous scapular pain for longer than 12 weeks (chronic) and that at least one trigger point will be present in the scapular region (serratus posterior superior, rhomboid groups, levator scapulae and trapezius muscles). Trigger points will be diagnosed as the presence of focal tenderness in a taut band and with pain recognition (Chatchawan et al., 2005; Tough et al., 2007). The participants will be able to follow instructions. Good communication and cooperation. Exclusion Criteria: 1. A history of the following diseases or disorders: Rotator cuff disease Cervical radiculopathy Degenerative shoulder joint disease Adhesive capsulitis of shoulder

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Scapular exercise<br>The participants will receive thirty minutes session of scapular exercise for 12 sessions | Other: scapular exercise<br> <br> * Other names: The participants will receive thirty minutes session of scapular exercise for 12 sessions;|
| No Intervention: Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pressure Pain Threshold as a measure by algometry |  | 6 Weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain scores on visual analog scale |  | 6 weeks | 
| Muscle tension on visual analog scale |  | 6 weeks | 
| Anxiety on State Anxiety Inventory |  | 6 weeks | 
| 24 hours pain intensity on Visual analog scale |  | 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Scapular exercises
Evaluation of Surgical Stress Index (SSI) During Sevoflurane/Remifentanil Anesthesia

Study Overview
=================
Brief Summary
-----------------
The aim of the present prospective randomized study was to challenge the ability of SSI to detect painful stimulation during sevoflurane - remifentanil anesthesia.

Detailed Description
-----------------
General anesthesia can be considered as a combination of hypnosis, antinociception and immobility. Whereas monitoring of depth of hypnosis, and muscle relaxation can be regarded as accepted, determination of the nociception is based on clinical signs like somatic or autonomic responses. Recently, the multivariate surgical stress index (SSI)has been demonstrated to correlate with surgical stress intensity. Thus, SSI might be a useful variable to adjust analgesic drug administration in individual patients. We want to investigate whether SSI is able to indicate nociception following standardized noxious stimulation during balanced sevoflurane - remifentanil anesthesia.

Conditions
-----------------
Analgesia

Intervention / Treatment
-----------------
* Procedure: standardized pain stimulus


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age between 18 and 65 years ASA physical status 1-2 elective surgery in general anesthesia of 1 to 2 hours written informed consent Exclusion Criteria: pregnancy history of cardiac arrhythmia presence of any neuromuscular or neurological disease use of CNS-active medication or abuse of alcohol or illicit drugs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: 1<br>increasing remifentanil administration | Procedure: standardized pain stimulus<br>* a tetanic stimulus (30s, 50 Hz, 60mA) applied as standardized pain stimulus<br>|
| Other: 2<br>decreasing remifentanil concentration | Procedure: standardized pain stimulus<br>* a tetanic stimulus (30s, 50 Hz, 60mA) applied as standardized pain stimulus<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SSI, compared to standard monitoring variables |  | during anesthesia | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Anesthesia General, Anesthetics Inhalation, Stress measurement, Surgical Stress, Diagnostic Techniques and Procedures
Ultrasonographic Bladder Wall Thickness and Different Forms of Detrusor Overactivity

Study Overview
=================
Brief Summary
-----------------
In the last decade, several authors proposed ultrasound measurement of Bladder wall thickness (BWT) for the screening of the voiding dysfunction and of the detrusor overactivity (DO). The aims of the investigator prospective study were: to compare the ultrasonographic measurement of BWT in women with DO vs women with other urodynamic diagnosis in a very large population. to verify whether the BWT in women with DO can be different in the clinically or urodinamically different forms of DO.

Official Title
-----------------
Ultrasonographic Bladder Wall Thickness and Different Forms of Detrusor Overactivity

Conditions
-----------------
Detrusor Overactivity

Intervention / Treatment
-----------------
* Other: ultrasonography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All women referred to our Urogynecology Unit from January 2005 to December 2008 for symptoms of OAB, stress urinary incontinence or mixed incontinence and sottoposte a prove urodinamiche complete were included in this prospective study Exclusion Criteria: The investigators excluded women with documented recurrent urinary tract infections Previous antimuscarinic treatment Previous pelvic surgery Neurological disease Vaginal prolapse > I stage Symptoms or clinical and/or urodynamic signs of voiding dysfunction Patients included in other ongoing clinical trials during the same study period.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| detrusor overactivity<br> | Other: ultrasonography<br>* transvaginal ultrasonography of bladder wall thickness<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 mg/DRSP 3 mg) on Quality of Life.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the effects on the quality of life and BMI of new contraceptives.

Detailed Description
-----------------
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.

Official Title
-----------------
A Multicentre, Open, Uncontrolled Study to Assess Quality of Life During Six Cycles (24 Weeks) of Treatment With an Oral Contraceptive Containing 30 µg of Ethinylestradiol and 3 mg of Drospirenone (Yasmin).

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Yasmin (30 µg EE, 3 mg Drospirenone, BAY86-5131)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female requiring contraceptives. Aged 18 to 35 if a non-smoker, aged 18 to 30 if a smoker. Regular menstrual cycle (defined as duration of 28 +/- 5 days). Exclusion Criteria: No Contraindication for OC use

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br> | Drug: Yasmin (30 µg EE, 3 mg Drospirenone, BAY86-5131)<br>* Yasmin, SH T 470 FA; 30 µg ethinylestradiol and 3 mg drospirenone, oral administration over 6 treatment cycles, one tablet per day for 21 days followed by a 7 day pill-free interval.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of Psychological General Well Being Questionnaire score |  | pretreatment cycle to cycle 6 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in body composition (evaluated by Multifrequency Bioelectrical Impedance Analysis) |  | pretreatment to cycle 6 | 
| Subject satisfaction with treatment at final visit |  | at final visit | 
| Subject evaluation of changes in greasy skin and greasy hair |  | baseline to cycle 6 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Females requiring contraceptives
Copeptin for Prediction of Treatment Response in Children With Monosymptomatic Nocturnal Enuresis (MEN).

Study Overview
=================
Brief Summary
-----------------
Monosymptomatic nocturnal enuresis (MEN) is a common problem in children, affecting 7-10% of all 7 year olds. MEN is often leading to psychosocial problems because of its burden and stigmatism. The only available medical treatment option is the vasopressin analogum Desmopressin®. However, according to the literature, only one third of patients shows a good treatment response, defined as more than 90% of reduced bed wetting. Furthermore, treatment with Desmopressin® may lead to psychosocial problems, high costs and potentially dangerous side effects like water intoxication and hypertension. Copeptin, mirroring arginine vasopressin (AVP), has been shown to be significantly lower in patients with MEN compared to controls and lower in patients with severe bed wetting compared to patients with only slight bed wetting.

Official Title
-----------------
Copeptin for Prediction of Treatment Response in Children With Monosymptomatic Nocturnal Enuresis (MEN).

Conditions
-----------------
Nocturnal Enuresis

Intervention / Treatment
-----------------
* Other: blood sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children at the age between 5 and 16 years Diagnosis of monosymptomatic nocturnal enuresis Completion of uroflowmetry and bladder sonography if possible Completion of home recording charts of bed wetting episodes if possible Willingness to use Desmopressin® treatment Exclusion Criteria: Children with daytime enuresis Children with lower urinary tract symptoms and infection Children with structural abnormalities of the urinary tract Children with chronic illness, esp. renal failure, hypertension, congenital heart disease, diabetes mellitus and diabetes insipidus.

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: blood sampling|At 4 visits capillary blood sampling for copeptin measurement will be performed with each child.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of copeptin at baseline and after 28 days during routine desmopressin therapy |  | morning and evening copeptin levels at baseline day 0 before routine desmopressin therapy and day 28 during routine desmopressin therapy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
children, desmopressin, copeptin
Pediatric Intubation With Difficult Airway

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to compare time, success rates of different video laryngoscopes for the emergency intubation with an immobilized cervical spine in a standardized pediatric manikin model.

Official Title
-----------------
Comparison of the Macintosh, Coopdech and AirTraq Laryngoscopes Using a Rigid Neck Collar in Pediatric Patients With Simulated Difficult Laryngoscopy.

Conditions
-----------------
Trauma, Intubation, Endotracheal

Intervention / Treatment
-----------------
* Device: MAC
* Device: Coopdech
* Device: AirTraq


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Give voluntary consent to participate in the study minimum 1 year of work experience in emergency medicine experienced emergency medical personnel (physicians, nurses, paramedics) Exclusion Criteria: Not meet the above criteria Wrist or Low back diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: intubation with immobilized cervical spine<br>endotracheal intubation with immobilized cervical spine | Device: MAC<br>* direct laryngoscopy<br>* Other names: Macintosh Laryngoscope;Device: Coopdech<br>* Video laryngoscopy<br>* Other names: Coopdech Video Lartyngoscope Portable VLP-100;Device: AirTraq<br>* optical laryngoscopy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Success of intubation | effectiveness of first, second and third intubation attempts and overall effectiveness of intubation by participants | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intubation time | time in seconds required for a successful intubation attempt | 1 day | 
| Cormack-Lehane grading | self-reported percentage the vocal cord visualization using the Cormack-Lehane grading (grade 1-4) | 1 day |
MACE and First Operating Room Systolic Blood Pressure in Patients Undergoing Non-cardiac Surgery Implications for the Hypertension Threshold

Study Overview
=================
Brief Summary
-----------------
To find the threshold of First operating room SBP above which MACE risk increases.

Detailed Description
-----------------
To find the threshold of First operating room SBP above which MACE risk increases. By reviewing data from 2012-2017 in PKU first hospital.

Official Title
-----------------
MACE and First Operating Room Systolic Blood Pressure in Patients Undergoing Non-cardiac Surgery Implications for the Hypertension Threshold

Conditions
-----------------
Major Adverse Cardiac-cerebral-kidney Event

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-100yr non-cardiac surgery Exclusion Criteria: missing data file

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| non-MACE<br>no MACE occurred | |
| MACE<br>MACE occurred | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MACE | major adverse cardiac-cerebral-kidney event | 30 days postoperatively |
Effect of Massage Treatment in Temporomandibular Joint

Study Overview
=================
Brief Summary
-----------------
Temporomandibular disorders (TMD) have multiple and broad clinical effects on orofacial structures and are often diagnosed in patients with a prevalence of between 5% and 12%. Among treatment options, massage therapy is one of the common therapeutic procedures and allows interesting clinical outcomes by reducing TMD symptoms successfully. However, there has been no attempt to validate this knowledge. Thus, the aim of this study is to evaluate the effect of massage and its properties in patients with TMD.

Official Title
-----------------
Effect of Massage Treatment in Patients With Temporomandibular Disorder

Conditions
-----------------
Massage Therapy, Temporomandibular Disorder

Intervention / Treatment
-----------------
* Other: Massage therapy
* Other: non-effective treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Temporomandibular disorder-positive RDC/TMD examination for groups RDC/TMD Ia and RDC/TMD Ib, Patient agreement to participate in the experimental study. Exclusion Criteria: RDC/TMD II and RDC/TMDIII, Drug and/or removable partial or total prosthesis wearers, Being submitted to any type of physiotherapeutic treatment, Incomplete dentition, History of systemic diseases as diabetes or arthritis, The occurrence of facial trauma, Refusal to assume responsibility with this research.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Test<br>Experimental group which employed with massage treatment | Other: Massage therapy<br>* Massage therapy performed by a physiotherapist<br>|
| Placebo Comparator: Placebo<br>Placebo group which employed with non-effective treatment | Other: non-effective treatment<br>* non-effective treatment<br>|
| No Intervention: Control<br>no treatment | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain- Visual Analog Scale | Self-reported pain values. High scores for pain mean worse outcome for the study. | 12 weeks-14 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Massage
Health Information Technology to Reduce Disparities in Adolescent Health Outcomes: A Pragmatic Trial

Study Overview
=================
Brief Summary
-----------------
We will compare differences in sexually transmitted infection (STI) detection rates between sexual health survey (SHS)-derived electronic clinical decision support (CDS) versus usual care (e.g. no provision of CDS) using an interrupted time series design. We hypothesize that population-based STI detection rates will be higher when SHS-derived electronic CDS is provided compared to usual care. Secondary analysis will include a comparison of STI detection rates by sexual risk strata (high risk vs. at risk) and race/ethnicity.

Official Title
-----------------
Leveraging Health Information Technology to Reduce Health Disparities in Adolescent Health Outcomes: A Patient-Centered Approach

Conditions
-----------------
Sexually Transmitted Diseases

Intervention / Treatment
-----------------
* Behavioral: SHS-derived CDS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adolescents aged 15-21 years seeking care in the emergency department Exclusion Criteria: Patients will be excluded if unable to understand English, are critically ill, cognitively impaired, or otherwise unable to provide consent for completion of the sexual health survey (SHS) and STI screening.

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: SHS-derived CDS<br>All adolescents seen in the emergency department that meet eligibility criteria will be offered the sexual health survey (SHS) during the pragmatic trial. | Behavioral: SHS-derived CDS<br>* This intervention will provide electronic clinical decision support for adolescents who screen at risk or at high risk of an STI.<br>|
| No Intervention: Usual care<br>All adolescents seen in the emergency department that meet eligibility criteria prior to implementation of SHS-derived CDS. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Chlamydia trachomatis (CT) / Neisseria gonorrhoeae (GC) detection rates | Proportion of encounters during which patients test positive for CT/GC; measured by urine-based nucleic acid amplification tests. | 3-7 days after emergency department (ED) visit | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| STI rates by race/ethnicity | Change in STI rates by race/ethnicity | 3-7 days after ED visit |